Joseph Patrick McEvoy

Professor

  • 25291 Citations
  • 78 h-Index
1978 …2019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 1978 2019

2019

34 Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities

Anderson, K. E., Stamler, D., Davis, M. D., Hauser, R. A., Jarskog, L. F., Jimenez-Shahed, J., Kumar, R., Ochudlo, S., McEvoy, J. P. & Fernandez, H. H., Feb 1 2019, In : CNS spectrums. 24, 1, 1 p.

Research output: Contribution to journalArticle

Open Access
Dopamine Antagonists
Comorbidity
Psychotic Disorders
Psychiatry
Mood Disorders

35 Long-term Improvements in Site-Rated Outcomes with Deutetrabenazine Treatment in Patients with Tardive Dyskinesia

Anderson, K. E., Stamler, D., Davis, M. D., Gross, N., Hauser, R. A., Jarskog, L. F., Jimenez-Shahed, J., Kumar, R., Ochudlo, S., McEvoy, J. P. & Fernandez, H. H., Feb 1 2019, In : CNS spectrums. 24, 1, p. 193-194 2 p.

Research output: Contribution to journalArticle

Open Access
Placebos
Therapeutics
Dyskinesias
deutetrabenazine
Tardive Dyskinesia
2 Citations (Scopus)

Characterizing treatment effects of valbenazine for tardive dyskinesia: Additional results from the KINECT 3 study

Correll, C. U., Cutler, A. J., Kane, J. M., McEvoy, J. P., Liang, G. S. & O'Brien, C. F., Jan 2019, In : Journal of Clinical Psychiatry. 80, 1

Research output: Contribution to journalArticle

Placebos
Body Regions
Diagnostic and Statistical Manual of Mental Disorders
Therapeutics
Odds Ratio
1 Citation (Scopus)

Heterogeneity of treatment effects of long-acting injectable antipsychotic medications

Stroup, T. S., Bareis, N. A., Rosenheck, R. A., Swartz, M. S. & McEvoy, J. P., Jan 2019, In : Journal of Clinical Psychiatry. 80, 1

Research output: Contribution to journalArticle

Antipsychotic Agents
Injections
Substance-Related Disorders
Therapeutics
Schizophrenia

The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders

McEvoy, J. P., Park, T., Schilling, T., Terasawa, E., Ayyagari, R. & Carroll, B., Jul 3 2019, In : Current Medical Research and Opinion. 35, 7, p. 1205-1214 10 p.

Research output: Contribution to journalArticle

Mental Disorders
Antipsychotic Agents
Inpatients
Delivery of Health Care
Tardive Dyskinesia
Clinical Trials, Phase I
Adipokines
Leukocyte Count
Antipsychotic Agents
Schizophrenia
2018
1 Citation (Scopus)

Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women with Psychosis: Results from the DAAMSEL Clinical Trial

Kelly, D. L., Powell, M. M., Wehring, H. J., Sayer, M. A., Kearns, A. M., Hackman, A. L., Buchanan, R. W., Nichols, R. B., Adams, H. A., Richardson, C. M., Vyas, G., McMahon, R. P., Earl, A. K., Sullivan, K. M., Liu, F., Luttrell, S. E., Dickerson, F. B., Feldman, S. M., Narang, S., Koola, M. M. & 3 others, Buckley, P. F., Rachbeisel, J. A. & McEvoy, J. P., Aug 1 2018, In : Journal of Clinical Psychopharmacology. 38, 4, p. 317-326 10 p.

Research output: Contribution to journalArticle

Prolactin
Psychotic Disorders
Clinical Trials
Placebos
Galactorrhea
4 Citations (Scopus)

Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels

Wehring, H. J., Elsobky, T., McEvoy, J. P., Vyas, G., Richardson, C. M., McMahon, R. P., DiPaula, B. A., Liu, F., Sullivan, K., Buchanan, R. W., Feldman, S., McMahon, E. M. & Kelly, D. L., Mar 1 2018, In : Psychiatric Quarterly. 89, 1, p. 73-80 8 p.

Research output: Contribution to journalArticle

Minocycline
Clozapine
Schizophrenia
Cytochrome P-450 CYP1A2
norclozapine

Evidence-Based Strategies for Managing Tardive Dyskinesia

McEvoy, J. P., Jan 1 2018, In : The Journal of clinical psychiatry. 79, 1

Research output: Contribution to journalArticle

Bipolar Disorder
Tardive Dyskinesia
7 Citations (Scopus)
Clinical Trials, Phase I
Cannabis
Psychopathology
Cocaine
Cognition
5 Citations (Scopus)

Revisiting the abnormal involuntary movement scale: Proceedings from the tardive dyskinesia assessment workshop

Kane, J. M., Correll, C. U., Nierenberg, A. A., Caroff, S. N., Sajatovic, M., Cutler, A. J., McEvoy, J. P. & Stacy, M., May 1 2018, In : Journal of Clinical Psychiatry. 79, 3, 17cs11959.

Research output: Contribution to journalArticle

Education
Clinical Trials
Telecommunications
Tardive Dyskinesia
Abnormal Involuntary Movement Scale
1 Citation (Scopus)

What You Should Know About Tardive Dyskinesia: Screening, Causes, and New Treatment Options

Manning, J. S. & McEvoy, J. P., Jan 1 2018, In : The Journal of clinical psychiatry. 79, 1

Research output: Contribution to journalArticle

Webcasts
Therapeutics
Tardive Dyskinesia
2017
61 Citations (Scopus)

Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial

Anderson, K. E., Stamler, D., Davis, M. D., Factor, S. A., Hauser, R. A., Isojärvi, J., Jarskog, L. F., Jimenez-Shahed, J., Kumar, R., McEvoy, J. P., Ochudlo, S., Ondo, W. G. & Fernandez, H. H., Aug 1 2017, In : The Lancet Psychiatry. 4, 8, p. 595-604 10 p.

Research output: Contribution to journalArticle

Dyskinesias
Placebos
Therapeutics
Dopamine Antagonists
Patient Safety
5 Citations (Scopus)

Durability of therapeutic response with long-term aripiprazole lauroxil treatment following successful resolution of an acute episode of Schizophrenia

McEvoy, J. P., Risinger, R., Mykhnyak, S., Du, Y., Liu, C. C., Stanford, A. D. & Weiden, P. J., Sep 1 2017, In : Journal of Clinical Psychiatry. 78, 8, p. 1103-1109 7 p.

Research output: Contribution to journalArticle

Schizophrenia
Therapeutic Uses
Therapeutics
aripiprazole lauroxil
Randomized Controlled Trials
2 Citations (Scopus)

Prioritizing Harm

Moyer, K. H., McEvoy, J. P., Mabe, P. A., Buchanan, E., Venkatesan, A. & Buckley, P. F., Jan 2 2017, In : Journal of Personality Assessment. 99, 1, p. 78-82 5 p.

Research output: Contribution to journalArticle

Personality
Psychotic Disorders
State Hospitals
Self Report
Inpatients

What's new in our understanding of schizophrenia

McEvoy, J. P., Feb 2017, In : Psychiatric Times. 34, 2

Research output: Contribution to journalArticle

Schizophrenia
2016
19 Citations (Scopus)

A guide to the management of clozapine-related tolerability and safety concerns

Citrome, L., McEvoy, J. P. & Saklad, S. R., Sep 1 2016, In : Clinical Schizophrenia and Related Psychoses. 10, 3, p. 163-177D

Research output: Contribution to journalReview article

Clozapine
Safety
Agranulocytosis
Sialorrhea
Enuresis
12 Citations (Scopus)

Brexpiprazole for the treatment of schizophrenia: A review of this novel serotonin-dopamine activity modulator

McEvoy, J. P. & Citrome, L., Dec 1 2016, In : Clinical Schizophrenia and Related Psychoses. 9, 4, p. 177-186 10 p.

Research output: Contribution to journalReview article

Dopamine
Serotonin
Schizophrenia
Placebos
Therapeutics
8 Citations (Scopus)

Cost-effectiveness of long-acting injectable paliperidone palmitate versus haloperidol decanoate in maintenance treatment of schizophrenia

Rosenheck, R. A., Leslie, D. L., Sint, K. J., Lin, H., Li, Y., McEvoy, J. P., Byerly, M. J., Hamer, R. M., Swartz, M. S. & Stroup, T. S., Oct 1 2016, In : Psychiatric Services. 67, 10, p. 1124-1130 7 p.

Research output: Contribution to journalArticle

Cost-Benefit Analysis
Quality-Adjusted Life Years
Schizophrenia
Injections
Antipsychotic Agents
2 Citations (Scopus)

Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia

Emsley, R., Fleischhacker, W. W., Galderisi, S., Halpern, L. J., McEvoy, J. P. & Schooler, N. R., Sep 9 2016, In : BMJ (Clinical research ed.). 354, p. i4728

Research output: Contribution to journalArticle

Drug and Narcotic Control
Secondary Prevention
Antipsychotic Agents
Schizophrenia
Placebos
6 Citations (Scopus)

The RAISE connection program: Psychopharmacological treatment of people with a first episode of schizophrenia

Kreyenbuhl, J. A., Medoff, D. R., McEvoy, J. P., Smith, T. E., Hackman, A. L., Nossel, I. R., Dixon, L. B., Essock, S. M. & Buchanan, R. W., Dec 1 2016, In : Psychiatric Services. 67, 12, p. 1300-1306 7 p.

Research output: Contribution to journalArticle

Antipsychotic Agents
Schizophrenia
Appointments and Schedules
Psychiatry
olanzapine
2 Citations (Scopus)

To the Editor

McEvoy, J. P., Oct 1 2016, In : JAMA Psychiatry. 73, 10, p. 1097-1098 2 p.

Research output: Contribution to journalLetter

2015
40 Citations (Scopus)

Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients with Persistent Symptoms

Kelly, D. L., Sullivan, K. M., McEvoy, J. P., McMahon, R. P., Wehring, H. J., Gold, J. M., Liu, F., Warfel, D., Vyas, G., Richardson, C. M., Fischer, B. A., Keller, W. R., Koola, M. M., Feldman, S. M., Russ, J. C., Keefe, R. S. E., Osing, J., Hubzin, L., August, S., Walker, T. M. & 1 others, Buchanan, R. W., Aug 11 2015, In : Journal of Clinical Psychopharmacology. 35, 4, p. 374-381 8 p.

Research output: Contribution to journalArticle

Minocycline
Clozapine
Schizophrenia
Brief Psychiatric Rating Scale
Placebos
1 Citation (Scopus)

Asenapine once daily versus twice daily: Impact on patient acceptance in a randomized, open-label, 14-day clinical trial

Sun, X., Hamer, R. & McEvoy, J., Jul 1 2015, In : Journal of Clinical Psychiatry. 76, 7, p. 992-993 2 p.

Research output: Contribution to journalLetter

Patient Satisfaction
Antipsychotic Agents
Young Adult
Schizophrenia
Clinical Trials
8 Citations (Scopus)

Randomized trial of the effect of four second-generation antipsychotics and one first-generation antipsychotic on cigarette smoking, alcohol, and drug use in chronic schizophrenia

Mohamed, S., Rosenheck, R. A., Lin, H., Swartz, M., McEvoy, J. P. & Stroup, S., Jul 1 2015, In : Journal of Nervous and Mental Disease. 203, 7, p. 486-492 7 p.

Research output: Contribution to journalArticle

Antipsychotic Agents
Schizophrenia
Smoking
Alcohols
Pharmaceutical Preparations
14 Citations (Scopus)
Clinical Trials, Phase I
Adipokines
Leukocyte Count
Antipsychotic Agents
Schizophrenia
2014

Antipsychotic medications for schizophrenia-reply

Stroup, T. S., McEvoy, J. P. & Hamer, R. M., Oct 8 2014, In : JAMA - Journal of the American Medical Association. 312, 14, 1 p.

Research output: Contribution to journalLetter

Isoxazoles
Palmitates
Haloperidol
Antipsychotic Agents
Schizophrenia
26 Citations (Scopus)

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: A 6-month, open-label, extension study

Citrome, L., Weiden, P. J., McEvoy, J. P., Correll, C. U., Cucchiaro, J., Hsu, J. & Loebel, A., Aug 2014, In : CNS spectrums. 19, 4, p. 330-339 10 p.

Research output: Contribution to journalArticle

Antipsychotic Agents
Schizophrenia
Psychotic Disorders
Psychomotor Agitation
Lurasidone Hydrochloride
72 Citations (Scopus)

Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: A randomized clinical trial

McEvoy, J. P., Byerly, M., Hamer, R. M., Dominik, R., Swartz, M. S., Rosenheck, R. A., Ray, N., Lamberti, J. S., Buckley, P. F., Wilkins, T. M. & Stroup, T. S., Jan 1 2014, In : JAMA - Journal of the American Medical Association. 311, 19, p. 1978-1986 9 p.

Research output: Contribution to journalArticle

Schizophrenia
Antipsychotic Agents
Randomized Controlled Trials
Injections
Psychomotor Agitation
5 Citations (Scopus)

Quantitative levels of aripiprazole parent drug and metabolites in urine

McEvoy, J. P., Millet, R. A., Dretchen, K., Morris, A. A., Corwin, M. J. & Buckley, P. F., Jan 1 2014, In : Psychopharmacology. 231, 23, p. 4421-4428 8 p.

Research output: Contribution to journalArticle

Parents
Urine
Pharmaceutical Preparations
Specific Gravity
Creatinine
2013
8 Citations (Scopus)

Clozapine for self-injurious behavior in individuals with borderline personality disorder

Zarzar, T. & McEvoy, J., Oct 2013, In : Therapeutic Advances in Psychopharmacology. 3, 5, p. 272-274 3 p.

Research output: Contribution to journalArticle

Self-Injurious Behavior
Borderline Personality Disorder
Clozapine
Aggression
State Hospitals
40 Citations (Scopus)

Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: A randomized, 6-week, open-label study

McEvoy, J. P., Citrome, L., Hernandez, D., Cucchiaro, J., Hsu, J., Pikalov, A. & Loebel, A., Feb 2013, In : Journal of Clinical Psychiatry. 74, 2, p. 170-179 10 p.

Research output: Contribution to journalArticle

Psychotic Disorders
Antipsychotic Agents
Schizophrenia
Treatment Failure
Psychomotor Agitation
44 Citations (Scopus)

Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia

Jarskog, L. F., Dong, Z., Kangarlu, A., Colibazzi, T., Girgis, R. R., Kegeles, L. S., Barch, D. M., Buchanan, R. W., Csernansky, J. G., Goff, D. C., Harms, M. P., Javitt, D. C., Keefe, R. S., McEvoy, J. P., McMahon, R. P., Marder, S. R., Peterson, B. S. & Lieberman, J. A., Jun 1 2013, In : Neuropsychopharmacology. 38, 7, p. 1245-1252 8 p.

Research output: Contribution to journalArticle

Choline
Prefrontal Cortex
Schizophrenia
Cognition
Creatine
17 Citations (Scopus)

Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: Results from a randomized controlled trial

Stroup, T. S., Byerly, M. J., Nasrallah, H. A., Ray, N., Khan, A. Y., Lamberti, J. S., Glick, I. D., Steinbook, R. M., McEvoy, J. P. & Hamer, R. M., May 1 2013, In : Schizophrenia Research. 146, 1-3, p. 190-195 6 p.

Research output: Contribution to journalArticle

olanzapine
Risperidone
Coronary Disease
Randomized Controlled Trials
Cardiovascular Diseases
10 Citations (Scopus)

High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: The ZEBRAS study

Goff, D. C., McEvoy, J. P., Citrome, L., Mech, A. W., Bustillo, J. R., Gil, R., Buckley, P., Manschreck, T. C., Achtyes, E. D. & Macklin, E. A., Aug 1 2013, In : Journal of Clinical Psychopharmacology. 33, 4, p. 485-490 6 p.

Research output: Contribution to journalArticle

Schizophrenia
Serum
Blood Pressure
ziprasidone
Psychotic Disorders
55 Citations (Scopus)

Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics

McEvoy, J. P., Baillie, R. A., Zhu, H., Buckley, P. F., Keshavan, M. S., Nasrallah, H. A., Dougherty, G. G., Yao, J. K. & Kaddurah-Daouk, R., Jul 24 2013, In : PloS one. 8, 7, e68717.

Research output: Contribution to journalArticle

Antipsychotic Agents
Schizophrenia
Unsaturated Fatty Acids
Omega-3 Fatty Acids
polyunsaturated fatty acids
76 Citations (Scopus)

Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder

Jarskog, L. F., Hamer, R. M., Catellier, D. J., Stewart, D. D., LaVange, L., Ray, N., Golden, L. H., Lieberman, J. A., Stroup, T. S., Adler, L., Burnie, G., Barber, M., Byerly, M., Canive, J. M., Glick, I., Henderson, D. C., Lamberti, J. S., Khan, A., McEvoy, J. P., Meltzer, H. & 6 others, Miller, A., Miller, D. D., Nasrallah, H. A., Olson, S., Patel, J. K. & Saltz, B. L., Sep 1 2013, In : American Journal of Psychiatry. 170, 9, p. 1032-1040 9 p.

Research output: Contribution to journalArticle

Metformin
Psychotic Disorders
Weight Loss
Schizophrenia
Outpatients
24 Citations (Scopus)

Persistent infection with neurotropic herpes viruses and cognitive impairment

Watson, A. M. M., Prasad, K. M., Klei, L., Wood, J. A., Yolken, R. H., Gur, R. C., Bradford, L. D., Calkins, M. E., Richard, J., Edwards, N., Savage, R. M., Allen, T. B., Kwentus, J., McEvoy, J. P., Santos, A., Wiener, H. W., Go, R. C. P., Perry, R. T., Nasrallah, H. A., Gur, R. E. & 2 others, Devlin, B. & Nimgaonkar, V. L., May 1 2013, In : Psychological Medicine. 43, 5, p. 1023-1031 9 p.

Research output: Contribution to journalArticle

Viruses
Human Herpesvirus 1
Virus Diseases
Encephalitis
Infection
8 Citations (Scopus)

Principal components of heritability from neurocognitive domains differ between families with schizophrenia and control subjects

Wiener, H., Klei, L., Calkins, M., Wood, J., Nimgaonkar, V., Gur, R., DiAnne Bradford, L., Richard, J., Edwards, N., Savage, R., Kwentus, J., Allen, T., McEvoy, J. P., Santos, A., Gur, R., Devlin, B. & Go, R., Mar 1 2013, In : Schizophrenia Bulletin. 39, 2, p. 464-471 8 p.

Research output: Contribution to journalArticle

Schizophrenia
Population Control
Short-Term Memory
Individuality
African Americans
2012
19 Citations (Scopus)

Associations between purine metabolites and clinical symptoms in schizophrenia

Yao, J. K., Condray, R., Dougherty, G. G., Keshavan, M. S., Montrose, D. M., Matson, W. R., McEvoy, J. P., Kaddurah-Daouk, R. & Reddy, R. D., Aug 14 2012, In : PloS one. 7, 8, e42165.

Research output: Contribution to journalArticle

purines
Metabolites
signs and symptoms (animals and humans)
Schizophrenia
metabolites

Current standard treatments

McEvoy, J. P., Jun 1 2012, Pharmacological Treatments in Schizophrenia. Future Medicine Ltd., p. 15-25 11 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

32 Citations (Scopus)

Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: An open-label, randomized controlled trial

Covell, N. H., McEvoy, J. P., Schooler, N. R., Stroup, T. S., Jackson, C. T., Rojas, I. A. & Essock, S. M., May 2012, In : Journal of Clinical Psychiatry. 73, 5, p. 669-675 7 p.

Research output: Contribution to journalArticle

Risperidone
Microspheres
Randomized Controlled Trials
Injections
Prolactin
78 Citations (Scopus)

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia

Javitt, D. C., Buchanan, R. W., Keefe, R. S. E., Kern, R., McMahon, R. P., Green, M. F., Lieberman, J., Goff, D. C., Csernansky, J. G., McEvoy, J. P., Jarskog, F., Seidman, L. J., Gold, J. M., Kimhy, D., Nolan, K. S., Barch, D. S., Ball, M. P., Robinson, J. & Marder, S. R., Apr 1 2012, In : Schizophrenia Research. 136, 1-3, p. 25-31 7 p.

Research output: Contribution to journalArticle

Cognition
Schizophrenia
Peptides
Consensus
Placebos
16 Citations (Scopus)

Evaluation of HLA polymorphisms in relation to schizophrenia risk and infectious exposure

Bamne, M., Wood, J., Chowdari, K., Watson, A. M., Celik, C., Mansour, H., Klei, L., Gur, R. C., Bradford, L. D., Calkins, M. E., Santos, A., Edwards, N., Kwentus, J., McEvoy, J. P., Allen, T. B., Savage, R. M., Nasrallah, H. A., Gur, R. E., Perry, R. T., Go, R. C. P. & 3 others, Devlin, B., Yolken, R. & Nimgaonkar, V. L., Nov 1 2012, In : Schizophrenia Bulletin. 38, 6, p. 1149-1154 6 p.

Research output: Contribution to journalArticle

HLA Antigens
Single Nucleotide Polymorphism
Schizophrenia
Genome-Wide Association Study
Human Herpesvirus 1
72 Citations (Scopus)

Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia

Need, A. C., McEvoy, J. P., Gennarelli, M., Heinzen, E. L., Ge, D., Maia, J. M., Shianna, K. V., He, M., Cirulli, E. T., Gumbs, C. E., Zhao, Q., Campbell, C. R., Hong, L., Rosenquist, P., Putkonen, A., Hallikainen, T., Repo-Tiihonen, E., Tiihonen, J., Levy, D. L., Meltzer, H. Y. & 1 others, Goldstein, D. B., Aug 10 2012, In : American journal of human genetics. 91, 2, p. 303-312 10 p.

Research output: Contribution to journalArticle

Exome
Schizophrenia
Genome-Wide Association Study
Psychotic Disorders
Sample Size
4 Citations (Scopus)

Heritability of functioning in families with schizophrenia in relation to neurocognition

Savage, R. M., Wiener, H. W., Nimgaonkar, V., Devlin, B., Calkins, M. E., Gur, R. E., O'Jile, J., Bradford, L. D., Edwards, N., Kwentus, J., Allen, T., McEvoy, J. P., Nasrallah, H., Santos, A., Aduroja, T., Lahti, A., May, R. S., Montgomery-Barefield, L. & Go, R. C. P., Aug 1 2012, In : Schizophrenia Research. 139, 1-3, p. 105-109 5 p.

Research output: Contribution to journalArticle

Schizophrenia
African Americans
Demography
Marital Status
Cognition
39 Citations (Scopus)

Impaired plasmalogens in patients with schizophrenia

Kaddurah-Daouk, R., McEvoy, J. P., Baillie, R., Zhu, H., K. Yao, J., Nimgaonkar, V. L., Buckley, P. F., Keshavan, M. S., Georgiades, A. & Nasrallah, H. A., Aug 15 2012, In : Psychiatry Research. 198, 3, p. 347-352 6 p.

Research output: Contribution to journalArticle

Plasmalogens
Schizophrenia
Healthy Volunteers
Glycerophospholipids
Recurrence
9 Citations (Scopus)

Optimizing outcome with antipsychotic treatment in first-episode schizophrenia: Balancing efficacy and side effects

Freudenreich, O. & McEvoy, J. P., Oct 1 2012, In : Clinical Schizophrenia and Related Psychoses. 6, 3, p. 115-121 7 p.

Research output: Contribution to journalReview article

Antipsychotic Agents
Schizophrenia
Psychotic Disorders
Therapeutics
Clozapine
19 Citations (Scopus)

Religious coping and quality of life among individuals living with schizophrenia

Nolan, J. A., McEvoy, J. P., Koenig, H. G., Hooten, E. G., Whetten, K. & Pieper, C. F., Oct 1 2012, In : Psychiatric Services. 63, 10, p. 1051-1054 4 p.

Research output: Contribution to journalArticle

Schizophrenia
Quality of Life
Southeastern United States
Psychology
Cultural Competency
2011
57 Citations (Scopus)

3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia

Condray, R., Dougherty, G. G., Keshavan, M. S., Reddy, R. D., Haas, G. L., Montrose, D. M., Matson, W. R., McEvoy, J. P., Kaddurah-Daouk, R. & Yao, J. K., Jul 1 2011, In : International Journal of Neuropsychopharmacology. 14, 6, p. 756-767 12 p.

Research output: Contribution to journalArticle

Tryptophan
Antipsychotic Agents
Schizophrenia
Kynurenic Acid
Kynurenine